UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027704
Receipt number R000031735
Scientific Title Prediction of requirement of hypoglycemic therapies for hyperglycemia induced by steroidal treatment for collagen vascular disease, etc.
Date of disclosure of the study information 2017/06/09
Last modified on 2017/06/09 13:35:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prediction of requirement of hypoglycemic therapies for hyperglycemia induced by steroidal treatment for collagen vascular disease, etc.

Acronym

Developing and validation of the scoring system for prediction of requirement of hypoglycemic therapies including insulin for hyperglycemia during glucocorticoid treatment (Multicenter Retrospective Study)

Scientific Title

Prediction of requirement of hypoglycemic therapies for hyperglycemia induced by steroidal treatment for collagen vascular disease, etc.

Scientific Title:Acronym

Developing and validation of the scoring system for prediction of requirement of hypoglycemic therapies including insulin for hyperglycemia during glucocorticoid treatment (Multicenter Retrospective Study)

Region

Japan


Condition

Condition

Glucocorticoid-induced diabetes

Classification by specialty

Medicine in general Endocrinology and Metabolism Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Developing and validation of the scoring system for prediction of insulin requirement for hyperglycemia during glucocorticoid treatment.

Basic objectives2

Others

Basic objectives -Others

Compare the following clinical parameters; sex,age,fever,weight,height,body mass index,underlying diseases,laboratory data (total protein,albumin,aspartate aminotransferase,alanine aminotransferase,lactate dehydrogenase,alkaline phosphatase,gamma glutamyl transpeptidase,creatinine,uric acid,urea nitrogen,C reactive protein, HbA1c,fasting plasma glucose White blood cell count,white blood cell differentiation,red blood cell count,hemoglobin,platelet count),and initial dose of glucocorticoid (in terms of PSL mg/day),and pulse therapy between insulin and non-insulin groups in the Developing set.Subsequently,develop scoring system according to statistical analyses of these parameters in the Developing set.

Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Administration of insulin therapy during
glucocorticoid treatment

Key secondary outcomes

Administration of oral hypoglycemic agentsand glucagon like peptide 1 receptor agonist


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Developing set
patients admitted in Department of General Internal Medicine, Gifu University Hospital between 1 June 2004 and 31 July 2016.

Validation set
A: admitted in Department of General Internal Medicine, Gifu Prefectural General Medical Center between 1 April 2012 and 31 July 2016.
B: admitted in Center of General Internal Medicine and Rheumatology, Gifu Municipal Hospital between 1 April 2012 and 31 July 2016.

Inclusion criteria applied to the Developing set, and Validation set A and B indicate that patients were 20 years of age or older and the glucocorticoid treatment with the dosage of prednisolone more than 5 mg/day for 4 weeks at least was administered for the first time.

Key exclusion criteria

Exclusion criterion indicates taking concomitantly anti-cancer drugs

Target sample size

700


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hiroyuki Morita

Organization

Gifu University Hospital

Division name

Department of General Internal Medicine

Zip code


Address

1-1 Yanagido, Gifu

TEL

058-230-6632

Email

hmorita@gifu-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Mikako Kawashima

Organization

Gifu University Hospital

Division name

Department of General Internal Medicine

Zip code


Address

1-1 Yanagido, Gifu

TEL

058-230-6632

Homepage URL


Email

oida@gifu-u.ac.jp


Sponsor or person

Institute

Gifu University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)

None


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

岐阜大学医学部附属病院総合内科(岐阜県)
岐阜県総合医療センター内科・総合診療科(岐阜県)
岐阜市民病院総合内科・膠原病内科(岐阜県)


Other administrative information

Date of disclosure of the study information

2017 Year 06 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 06 Month 09 Day

Date of IRB


Anticipated trial start date

2017 Year 06 Month 09 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Develop the scoring system for prediction of insulin requirement during glucocorticoid treatment by retrospective observational study based on the medical record information of inpatients who received glucocorticoid therapy in Department of General Internal Medicine, Gifu University Hospital between 1 June 2004 and 31 July 2016 (Developing set).
Subsequently,
evaluate clinical utility and varidity of the scoring system, according to retrospective analyses of medical record information of inpatients who received glucocorticoid therapy in Department of General Internal Medicine, Gifu Prefectural General Medical Center between 1 April 2012 and 31 July 2016, and Center of General Internal Medicine and Rheumatology, Gifu Municipal Hospital between 1 April 2012 and 31 July 2016, respectively.(Validation set A and B)


Management information

Registered date

2017 Year 06 Month 09 Day

Last modified on

2017 Year 06 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031735


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name